OverviewSuggest Edit

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. Biogen markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis, FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy.
... Show more
TypePublic
Founded1978
HQCambridge, US
Websitebiogen.com
Employee Ratings3.5

Latest Updates

Employees (est.) (Nov 2018)7,300
Job Openings466
Revenue (FY, 2016)$11.4 B(+7%)
Share Price (Feb 2019)$332.9 (+4%)

Key People/Management at Biogen

Michel Vounatsos

Michel Vounatsos

CEO
Susan Alexander

Susan Alexander

EVP
Jeffrey Capello

Jeffrey Capello

EVP
Michael Ehlers

Michael Ehlers

EVP
Ginger Gregory

Ginger Gregory

EVP
Chirfi Guindo

Chirfi Guindo

EVP
Show more

Biogen Office Locations

Biogen has an office in Cambridge
Cambridge, US (HQ)
225 Binney St
Show all (1)
Report incorrect company information

Biogen Financials and Metrics

Biogen Revenue

Biogen's revenue was reported to be $11.45 b in FY, 2016 which is a 6.4% increase from the previous period.
USD

Revenue (Q1, 2017)

2.8b

Net income (Q1, 2017)

747.5m

EBIT (Q1, 2017)

1.0b

Market capitalization (15-Feb-2019)

65.5b

Closing stock price (15-Feb-2019)

332.9

Cash (31-Mar-2017)

924.0m
Biogen's current market capitalization is $65.5 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

6.9b9.7b10.8b11.4b

Revenue growth, %

40%11%6%

General and administrative expense

1.9b

R&D expense

2.0b
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

2.4b2.5b2.6b2.6b2.8b2.7b2.9b3.0b2.8b

General and administrative expense

576.6m570.4m560.4m491.9m477.8m497.3m492.4m462.7m499.1m

R&D expense

447.3m417.2m460.5m490.7m519.9m437.3m473.1m529.0m423.4m

Operating expense total

1.0b987.6m1.0b982.6m997.7m934.6m965.5m991.7m922.5m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

602.6m1.2b1.3b2.3b

Accounts Receivable

824.4m1.3b1.2b1.4b

Inventories

659.0m804.0m893.4m1.0b

Current Assets

3.2b4.7b6.7b8.7b
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

863.2m1.2b1.5b1.3b4.1b1.1b1.4b2.1b924.0m

Accounts Receivable

1.0b1.1b1.4b1.3b1.3b1.4b1.3b1.5b1.5b

Inventories

715.9m753.1m825.3m865.7m918.9m964.6m996.4m1.0b921.6m

Current Assets

3.9b4.4b5.3b5.6b9.3b7.2b7.4b8.1b6.9b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

1.9b2.9b3.6b3.7b

Depreciation and Amortization

688.2m600.4m682.7m

Inventories

(240.0m)(190.0m)(170.0m)(165.6m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

723.1m856.1m820.2m924.8m1.0b969.2m1.0b1.0b747.5m

Inventories

865.7m918.9m964.6m996.4m1.0b921.6m

Accounts Payable

282.7m251.2m271.3m225.9m274.0m316.4m
USDY, 2017

Revenue/Employee

379.8k

Financial Leverage

1.8 x
Show all financial metrics

Biogen Operating Metrics

Biogen's Training Provided, no. of people was reported to be 40 k in FY, 2016.
FY, 2016

Phase I Trials Products

4

Phase II Trials Products

10

Phase III Trials Products

2

Training Provided, no. of people

40 k
Show all operating metrics

Biogen Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
AliveGenJuly 25, 2018$27.50 m
Karyopharm TherapeuticsJanuary 25, 2018$10 m
Report incorrect company information

Biogen Online and Social Media Presence

Embed Graph
Report incorrect company information

Biogen News and Updates

Cell and Gene Therapy Market – Major Technology Giants in Buzz Again | Amgen, Biogen, BioMarin Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis

The “Global Cell and Gene Therapy Market” provides up-to-date information on current and future industry trends, enabling readers to identify products and services to increase revenue growth and profitability. Posted via Industry Today. Follow us on Twitter @IndustryToday

Biosimilar Drugs Market Growth & Key Business Strategies by Leading Industry Players Novartis, Celltrion, Biocon, Hospira, Merck Serono, Biogen idec, Genentech

Biosimilar Drugs market report gives a detailed overview of the dynamics of the industries, which impacts on the growth of businesses. The study comprises a blend of various segments such as drivers, restraints, and opportunities. The effective strategies are implemented by the various top-level key…

Bio-pharma Market to witness astonishing growth of 10.1% including key players Sanofi, Amgen, AbbVie, Merck, Biogen Idec

Advance Market Analytics, a global market research and consulting organization, have released a new study titled "Bio-pharma market - Global outlook to 2024". The study highlights influencing factors that are impacting or reinforcing market environment such as Government Policy, technological change…

Biogen stock declines as patent office says Mylan patent win likely

Biogen Inc. shares declined in the extended session Wednesday after the U.S. Patent and Trademark Office said Mylan NV could likely succeed in a patent challenge to a Biogen multiple sclerosis drug. Biogen shares fell 2.8% after hours, following a 1.1% decline to close at $333.24. In a decision, th…

Biogen Slips as Roche Spikes Alzheimer's Trials on Weak Data

Biogen Slips as Roche Spikes Alzheimer's Trials on Weak Results

Biogen stock up 3% after 4Q earnings beat

Shares of Biogen Inc. gained 3% in premarket trade Tuesday after the company reported fourth-quarter earnings that beat profit and revenue expectations. Profit for the latest quarter rose to $944.9 million, or $4.73 a share, after a loss of $166.3 million, or a loss of $1.40, in the year-ago quart…
Show more
Report incorrect company information

Biogen Blogs

Biogen to Present at the 37th Annual J.P. Morgan Healthcare Conference

Cambridge, MA, - -  Biogen Inc.   (NASDAQ: BIIB) announced today that it will present at the 37 th Annual J.P. Morgan Healthcare Conference. The webcast will be live on Monday, January 7, 2019 at 3:30 p.m. PST, 6:30 p.m. EST.  To access the live webcast, please visit Biogen’s Investors section at

Biogen to Report Fourth Quarter and Year-End 2018 Financial Results January 29, 2019

Biogen to Report Fourth Quarter and Year-End 2018 Financial Results January 29, 2019 Ray.Beron@west.com Mon, 12/10/2018 - 12:32 Biogen to Report Fourth Quarter and Year-End 2018 Financial Results January 29, 2019 December 10, 2018 at 4:05 PM EST This release i…

Biogen to Present at the Evercore ISI HealthConX

Cambridge, MA, - - Biogen Inc. (Nasdaq:BIIB) announced today that it will present at the Evercore ISI HealthConX. The webcast will be live on Wednesday, November 28, 2018 at 9:30 a.m. ET. To access the live webcast, please visit Biogen’s Investors section at http://investors.biogen.com/ .

Biogen To Host Investor Webcast On Its Multiple Sclerosis Portfolio On December 12, 2018

Cambridge, Mass. – November 19, 2018 – Biogen (Nasdaq: BIIB) today announced it will host a live webcast and Q&A session to review its portfolio of commercial therapies and investigational new compounds for the treatment of multiple sclerosis.   The live webcast will begin at 8:00 a.m.

Biogen Advances Research to Improve Outcomes for Patients With Multiple Sclerosis

Evidence supports potential of serum neurofilament light (sNfL) as clinically useful biomarker in MS; Biogen and Siemens Healthineers collaborate to develop sNfL blood test Real-world data add to the large body of evidence establishing the long-term effectiveness of TECFIDERA and TYSABRI, including

New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy

NURTURE study participants were alive and did not require permanent ventilation, in contrast to natural history of spinal muscular atrophy (SMA) Study participants achieved motor milestones with 100 percent sitting independently and 88 percent able to walk Additional data feature biomarkers as an
Show more

Biogen Company Life and Culture

Report incorrect company information

Biogen Frequently Asked Questions

  • When was Biogen founded?

    Biogen was founded in 1978.

  • Who are Biogen key executives?

    Biogen's key executives are Michel Vounatsos, Susan Alexander and Jeffrey Capello.

  • How many employees does Biogen have?

    Biogen has 7,300 employees.

  • What is Biogen revenue?

    Latest Biogen annual revenue is $11.4 b.

  • What is Biogen revenue per employee?

    Latest Biogen revenue per employee is $1.6 m.

  • Who are Biogen competitors?

    Competitors of Biogen include Regeneron Pharmaceuticals, Gilead Sciences and Amgen.

  • Where is Biogen headquarters?

    Biogen headquarters is located at 225 Binney St, Cambridge.

  • Where are Biogen offices?

    Biogen has an office in Cambridge.

  • How many offices does Biogen have?

    Biogen has 1 office.